Rhythm Pharmaceuticals Aktie
WKN DE: A2H5A0 / ISIN: US76243J1051
07.04.2025 13:14:45
|
Rhythm Pharma Reports Positive Topline Results From Phase 3 TRANSCEND Trial With Setmelanotide
(RTTNews) - Rhythm Pharmaceuticals (RYTM) reported positive topline results from the Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor agonist, for the treatment of acquired hypothalamic obesity. The trial met primary endpoint with a statistically significant and highly clinically meaningful reduction in body mass index with setmelanotide in both adult and pediatric patients versus placebo. No new safety signals were observed, in line with setmelanotides well-established and well-understood safety profile.
Rhythm expects presenting full data from the TRANSCEND study at an upcoming medical meeting.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Rhythm Pharmaceuticals Incmehr Nachrichten
04.08.25 |
Ausblick: Rhythm Pharmaceuticals stellt Zahlen zum jüngsten Quartal vor (finanzen.net) |
Analysen zu Rhythm Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
Rhythm Pharmaceuticals Inc | 83,50 | 2,45% |
|